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Introduction: The combination antiretroviral therapy (cART) has led to decreased opportunistic infections and hospital
admissions in human immunodeficiency virus (HIV)-infected patients, but the intensive care unit (ICU) admission rate
remains constant (or even increased in some instances) during the cART era. Hepatitis C virus (HCV) infection is
associated with an increased risk for hospital admission and/or mortality (particularly those related to severe liver
disease) compared with the general population. The aim of this study was to assess the mortality among HIV-infected
patients in ICU, and to evaluate the impact of HIV/HCV coinfection and severe sepsis on ICU mortality.
Methods: We carried out a retrospective study based on patients admitted to ICU who were recorded in the
Minimum Basic Data Set (2005 through 2010) in Spain. HIV-infected patients (All-HIV-group (n = 1,891)) were
divided into two groups: HIV-monoinfected patients (HIV group (n = 1,191)) and HIV/HCV-coinfected patients
(HIV/HCV group (n = 700)). A control group (HIV(-)/HCV(-)) was also included (n = 7,496).
Results: All-HIV group had higher frequencies of severe sepsis (57.7% versus 39.4%; P < 0.001) than did the control
group. Overall, ICU mortality in patients with severe sepsis was much more frequent than that in patients without
severe sepsis (other causes) at days 30 and 90 in HIV-infected patients and the control group (P < 0.001). Moreover,
the all-HIV group in the presence or absence of severe sepsis had a higher percentage of death than did the
control group at days 7 (P < 0.001), 30 (P < 0.001) and 90 (P < 0.001). Besides, the HIV/HCV group had a higher
percentage of death, both in patients with severe sepsis and in patients without severe sepsis compared with the
HIV group at days 7 (P < 0.001) and 30 (P < 0.001), whereas no differences were found at day 90. In a bayesian
competing-risk model, the HIV/HCV group had a higher mortality risk (adjusted hazard ratio (aHR) = 1.44 (95%
CI = 1.30 to 1.59) and aHR = 1.57 (95% CI = 1.38 to 1.78) for patients with and without severe sepsis, respectively).
Conclusions: HIV infection was related to a higher frequency of severe sepsis and death among patients admitted
to the ICU. Besides, HIV/HCV coinfection contributed to an increased risk of death in both the presence and the
absence of severe sepsis.Introduction
The introduction of combination antiretroviral therapy
(cART) has dramatically decreased the morbidity/mor-
tality associated with human immunodeficiency virus
(HIV) infection in industrialized countries, leading to a
higher prevalence of persons living with HIV [1]. Further-
more, cART leads to decreased opportunistic infections* Correspondence: sresino@isciii.es
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unless otherwise stated.and hospital admissions [2,3]; but the intensive care unit
(ICU) admission rate remains constant (or even increased
in some instances) during the cART era [4-6]. This may
be explained by the fact that HIV-infected patients live
longer and are at higher risk of developing nonacquired
immunodeficiency syndrome (AIDS) comorbid illnesses,
as well as problems related to immune reconstitution
inflammatory response syndrome and toxicities related to
cART [4,7-9].
Moreover, the impact of HIV infection and cART on the
ICU mortality remains controversial [10]. Thus, Chiang
et al. [11] reported that outcome during the ICU stay wasal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ated with cART. However, Amâncio et al. [12] reported
that the in-ICU mortality was significantly associated with
cART in addition to comorbidities and septic shock.
Besides, several authors have reported that HIV-related
variables had scarce or no impact on death in patients ad-
mitted to the ICU, although they have been closely related
to the long-term outcome [5,8,13,14]. Moreover, although
Coquet et al. [15] reported an increased ICU survival in
the cART era, Vincent et al. [14] reported unchanged
overall ICU mortality, but significantly improved 3-month
survival of HIV-infected patients admitted to the ICU in
the cART era.
Hepatitis C virus (HCV) is an important cause of acute
and chronic hepatitis worldwide. Unfortunately, one fourth
of HCV-infected patients will progress to cirrhosis. HCV
infection remains the leading cause of decompensated cir-
rhosis, hepatocellular carcinoma, and liver transplantation
[16,17]. Chronic hepatitis C (CHC) is associated with an
increased risk for hospital admission and/or mortality, par-
ticularly those related to severe liver disease [18,19]. This
increased mortality rate still exists, even if HCV-specific
treatment is administered [9]. Around 20% of HIV-infected
individuals worldwide are chronically coinfected with
HCV, with coinfection rates reaching as high as 90% in
persons with a history of injection-drug use [20,21]. Be-
cause the course of HCV-associated liver disease may
be accelerated in HIV/HCV-coinfected patients, HCV
has emerged as a major cause of mortality in HIV/HCV-
coinfected patients on cART [22]. Fortunately, new direct
antiviral agents (DAAs) against HCV and the recognition
of genetic factors that determine HCV clearance are open-
ing a new era that has been compared with the cART era
for HIV infection [23].
The aim of this study was to assess the mortality in
HIV-infected patients admitted to the ICU during the
modern cART era, and to evaluate the impact of HIV/
HCV coinfection and severe sepsis on ICU mortality.
Materials and methods
Study design and data source
We carried out a retrospective cohort study of all
consecutive HIV-infected patients older than 18 years
who were admitted to the ICU in Spanish hospitals from
January 1, 2005, to December 31, 2010.
We also selected a control group of HIV-uninfected
patients admitted to the ICU in a proportion of 4:1 re-
garding to HIV-infected patients involved in the study.
This method increases the statistical power and the ac-
curacy of statistical tests [24-26] and is especially useful
with a limited number of events. The control group (se-
lective “cohort”) was obtained by random selection among
the patients older than 18 years with negative results for
HIV, HCV, and HBV testing. To avoid confoundingfactors, patients were matched for age, gender, trauma,
and surgical conditions. More specifically, the selection of
the control patients was performed by frequency [27],
quartiles of age of HIV-infected patients, and assuming an
approximate percentage of men and conditions influen-
cing health status (surgical conditions and trauma).
Data were obtained from the records of the Minimum
Basic Data Set (MBDS) of the National Surveillance Sys-
tem for Hospital Data in Spain, provided by the Spanish
Ministry of Health. The MBDS is a clinical and adminis-
trative database containing information obtained and re-
corded at time of hospital discharge, with an estimated
coverage of 97.7% and 25% of total hospital admissions to
public and private hospitals, respectively [28]. The MBDS
provides the encrypted patient identification number, sex,
date of birth, dates of hospital admission and discharge,
medical institutions providing the services, the diagnosis
and procedure codes according to the International
Classification of Diseases, 9th ed, Clinical Modification
(ICD-9-CM), and outcome at discharge [29].
The data were treated with full confidentiality, accord-
ing to Spanish legislation. MBDS is a nonpersonal data
extract that is mandatory for hospitals to guarantee the
epidemiologic knowledge necessary for driving national
health system management. This database is regulated
by an organic law that explains how institutions have to
proceed with health-related personal data. In this setting,
consent is not required because personal data are
collected for the exercise of the functions proper to
public administrations. The Spanish Ministry of Health
confirmed that our study fulfilled all ethical consider-
ations, according to Spanish legislation. The study was
approved by the Research Ethics Committee (Comité de
Ética de la Investigación y de Bienestar Animal) of the
Instituto de Salud Carlos III (Madrid, Spain).
ICD-9-CM codes and study groups
The ICD-9-CM codes that were used for defining the viral
infection status were as follows: (i) HIV infection (042 or
V08); (ii) HCV infection (ICD-9-CM codes 070.41, 070.44,
070.51, 070.54, 070.7x, or V02.62); and (iii) HBV infection
(ICD-9-CM codes 070.2x, 070.3x, or V02.61).
We selected patients admitted to the ICU who were
coded in the MBDS as MIV, which indicates Adult ICU.
HBV infection was a criterion for exclusion. Next, we
established several groups of patients according to their
HIV and HCV status: (i) control group (randomly selected
patients without HIV or HCV infections); (ii) all-HIV
group (patients with or without HCV coinfection), which
was divided into two groups: (a) HIV-monoinfected pa-
tients (HIV group) (patients exclusively infected with HIV
(HCV infection was excluded)); (b) HIV/HCV-coinfected
patients (HIV/HCV group) (patients exclusively coinfected
with HIV and HCV).
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The primary outcome was ICU mortality. The secondary
outcome was the presence of severe sepsis, which was de-
fined by the presence of an infection-associated diagnosis
and organ dysfunction, according to the criteria of Angus
et al. [30], by using ICD-9-CM codes (see Additional
file 1: Appendix 1 and 2, respectively. The MBDS provides
the ICD-9-CM codes for Angus implementation, but not
the date of diagnoses. Thus, we were unable to calculate
the date of onset of severe sepsis, and severe sepsis was re-
corded all over the hospital stay.
Length of stay was obtained as the difference, in days,
between date of hospital admission and date of discharge
or death in the ICU. The day of hospital admission was
considered day 0. Discharge on the same day was con-
sidered a 1-day stay. For patients admitted several times
to the ICU, only the first admission (also called the
index episode) was analyzed.
Statistical analysis
Overall, results are presented as the median and inter-
quartile range for continuous variables, and frequencies
and percentages for categoric data. HIV-infected patients
and HIV-uninfected patients were matched by frequen-
cies, which allowed the use of statistical tests for inde-
pendent groups. Categoric data and proportions were
analyzed by using the χ2 test or Fisher Exact test, as
required. A t test or Mann-Whitney U test was used to
compare continuous variables. All tests were two-tailed
with P values <0.05 considered significant.
The cumulative mortality rate at days 7, 30, and 90 in
patients with ICU admission was calculated without
considering censoring. This rate was estimated by divid-
ing the number of deaths by the number of patients ad-
mitted to the ICU. Log-linear modeling for contingency
tables was used to estimate main and interaction (mod-
erator) effects independently. Moreover, we also calcu-
lated the probability of ICU death after taking censoring
into account through a semiparametric bayesian model
of competing risk [31], which was used to evaluate the
association between HIV infection or HIV/HCV coinfec-
tion and the risk of ICU mortality, according to the
presence of severe sepsis: (a) risk of ICU mortality with
severe sepsis; and (b) risk of ICU mortality from other
causes (excluding severe sepsis). Inference in our bayes-
ian competing-risk model was based on Markov Chain
Monte Carlo (MCMC) simulation algorithms [32].
Moreover, we used the following covariates for adjusting
the model: (a) age, sex, trauma, surgical status, Charlson
Co-morbidity Index (CCI) (see Additional file 1: Appendix
3), and number of organ failures and sites of infection
(see Additional file 1: Appendix 4). This semiparametric
bayesian model provides the survival probabilities and the
hazard ratio (HR). When interpreting results on the basisof calculated survival probabilities, we took the presence
of competing risks (severe sepsis and death) into account
to prevent biased results [33].
All analyses were performed by using R statistical pack-
age version 3.0.2 (GNU General Public License; available
at [34]) and BayesX software version 2.1 (GNU General
Public License; available at [35]).
Results
Patient characteristics
Table 1 shows the epidemiologic and clinical characteris-
tics of patients included in this study. The all-HIV group
had a greater length of hospital stay than the control
group (P < 0.001), as well as higher frequencies of alcohol/
drug abuse, AIDS comorbidities (central nervous system
disease, Kaposi sarcoma, non-Hodgkin lymphoma, and
wasting syndrome) and CHC comorbidities (chronic liver
disease and cirrhosis and decompensated cirrhosis) (P <
0.05) (Table 1a). Regarding HIV subgroups, the HIV/HCV
group had higher frequencies of alcohol/drug abuse and
CHC-related comorbidities than the HIV group (P < 0.05);
whereas the HIV group had a longer hospital stay (P <
0.001) and a higher frequency of cancer (P < 0.05) than the
HIV/HCV group (Table 1b).
Table 2 shows the prevalence of processes related to se-
vere sepsis and opportunistic infections among patients ad-
mitted to the ICU in this study. The all-HIV group had a
higher frequency of severe sepsis (P < 0.001), acute organ
dysfunctions (except for neurologic dysfunction) (P < 0.05),
respiratory system infections (P < 0.001), central nervous
system infections (P < 0.001), and opportunistic infections
(P < 0.001) than the control group (Table 2a). Moreover,
the HIV/HCV group had a lower frequency of severe sepsis
(P = 0.028), respiratory system infections (P < 0.001), geni-
tourinary tract infections (P = 0.016), and opportunistic
infections (P < 0.001); and a higher frequency of neurologic
and hepatic dysfunction (P < 0.05), and digestive system
infections (P < 0.001) than the HIV group (Table 2b).
Mortality among patients admitted to the ICU
Table 3 shows the cumulative mortality rate at days 7,
30, and 90 in patients admitted to the ICU. Overall, the
ICU mortality in patients with severe sepsis was much
more frequent than in patients without severe sepsis
(other causes) at days 30 and 90 for both the all-HIV
group and the control group (P < 0.001; Table 3a), and the
HIV group and the HIV/HCV group (P < 0.001; Table 3b).
Moreover, the all-HIV group had a higher percentage
of death in all analyzed groups: all patients, patients with
severe sepsis, and patients without severe sepsis (other
causes) at days 7 (P < 0.001), 30 (P < 0.001), and 90 (P <
0.001) in comparison to the control group (Table 3a).
Besides, the HIV/HCV group had a higher percentage of
death for all patients, patients with severe sepsis, and
Table 1 Epidemiologic and clinical characteristics of patients admitted to the intensive care unit from 2005 to 2010
1a: Non-HIV versus all HIV patients 1b: HIV versus HIV/HCV patients
Control group All HIV group P value HIV group HIV/HCV group p-value
Number of patients 7,496 1,891 1,191 (63%) 700 (37%)
Gender (male) 5,827 (77.73%) 1,466 (77.52%) 0.869 911 (76.49%) 555 (79.28%) 0.177
Age (years) 44 (36-49) 43 (38-48) 0.064 43 (38-50) 43 (39-47) 0.060
Abuse of alcohol and drugs 2,453 (32.72%) 942 (49.81%) <0.001 494 (41.48%) 448 (64.00%) <0.001
Length of hospital stay (days) 5 (1-25) 7 (2-21) <0.001 9 (2-25) 5 (1-14) <0.001
Conditions influencing health status
Surgical conditions (V42, V45) 302 (4.02%) 80 (4.23%) 0.740 53 (4.45%) 27 (3.85%) 0.616
Trauma (E880* to E929*, E950 to E999*) 350 (4.66%) 97 (5.12%) 0.435 64 (5.37%) 33 (4.71%) 0.603
CHC-related comorbidities
Chronic liver disease and cirrhosis 851 (11.35%) 248 (13.11%) 0.036 106 (8.90%) 203 (29.00%) <0.001
Decompensated cirrhosis 736 (9.82%) 224 (11.85%) 0.010 82 (6.88%) 142 (20.29%) <0.001
Liver cancer 16 (0.21%) 8 (0.42%) 0.174 2 (0.17%) 6 (0.86%) 0.062
Liver transplant 48 (0.64%) 11 (0.58%) 0.900 3 (0.25%) 8 (1.14%) 0.031
AIDS-related comorbidities
Central nervous system disease 31 (0.41%) 24 (1.27%) <0.001 15 (1.26%) 9 (1.29%) 1
Cancer 73 (0.97%) 91 (4.81%) <0.001 72 (6.05%) 19 (2.71%) 0.002
Kaposi sarcoma - 27 (1.43%) NA 25 (2.10%) 2 (0.29%) 0.003
Non-Hodgkin lymphoma 73 (0.97%) 65 (3.44%) <0.001 49 (4.11%) 16 (2.29%) 0.048
Wasting syndrome 151 (2.01%) 98 (5.18%) <0.001 65 (5.46%) 33 (4.71%) 0.551
Values are expressed as absolute number (percentage) and median (percentile 25; percentile 75). Values were calculated by χ2 test and Mann-Whitney U test; and
P values in bold indicate statistically significant differences between groups. HCV, hepatitis C virus; HIV, human immunodeficiency virus.
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group at days 7 (P < 0.001) and 30 (P < 0.001), whereas no
differences were found at day 90 (Table 3b).
The possible interaction between the virologic status
(HIV-, HIV+, and HIV+/HCV+) and severe sepsis (present
and absent) for death at 7, 30, and 90 days was evaluated.
However, we did not find any significant interaction (data
not shown), analyzing the main effects independently.
Risk of death in the ICU among HIV-infected patients
Figure 1 shows the estimated survival function for patients
admitted to the ICU, stratified by HIV status (HIV/HCV
group versus HIV group), in the presence of competing
risks: (i) ICU mortality with severe sepsis (Figure 1A), and
(ii) ICU mortality from other causes (without severe sepsis)
(Figure 1B). The estimated survival was lower in the HIV/
HCV group than in the HIV group, regardless of the type
of competing risk considered. Thus, the HIV/HCV group
had higher mortality risk than the HIV group, both in pres-
ence of severe sepsis (adjusted hazard ratio (aHR) = 1.44
(95% CI = 1.30 to 1.59)) and in the absence of severe sepsis
(other causes) (aHR = 1.57 (95% CI = 1.38 to 1.78)).
Discussion
In this study, the major findings were as follows: (a) HIV-
infected patients (all-HIV group) had higher frequencies ofsevere sepsis and opportunistic infections than did HIV-
seronegative patients (control group); (b) HIV-infected
patients had higher mortality than did the control group,
independent of the presence of severe sepsis; (c) HIV/HCV
coinfection (about one third of HIV-infected patients) had
increased risk of ICU mortality, regardless of the presence
or absence of severe sepsis.
The spectrum of critical illness in HIV-infected pa-
tients has changed since the introduction of cART [2,3].
At the beginning of the HIV epidemic, patients admit-
ted to the ICU were mostly young individuals with
advanced AIDS-related diseases; but in the cART era,
the etiology of ICU admissions changed, whereby fewer
patients were admitted to the ICU as a result of oppor-
tunistic infections [8,14]. A continual shift occurred
toward ICU admissions for non-AIDS-related diagnoses
[4]. Among them, sepsis has been responsible for about
12% to 31% of HIV-infected patient admissions to
the ICU, and is associated with a worse prognosis
[11,36,37]. In our study, we found that HIV-infected
patients had a higher frequency of opportunistic infec-
tions than did patients in the control group; despite
being in the late period of cART. Additionally, HIV-
infected patients had higher frequency of severe sepsis,
worse prognosis, and a higher death rate than HIV-
seronegative subjects.
Table 2 Summary of diagnoses related to severe sepsis and opportunistic infections in the intensive care unit from
2005 to 2010
2a: Non-HIV versus all HIV patients 2b: HIV versus HIV/HCV patients
Control group All-HIV group P value HIV group HIV/HCV group P value
Severe sepsis 2,954 (39.41%) 1,092 (57.75%) <0.001 711 (59.70%) 381 (54.43%) 0.028
Acute organ dysfunction
Respiratory 4,882 (65.13%) 1,442 (76.26%) <0.001 917 (76.99%) 525 (75.00%) 0.353
Cardiovascular 2,463 (32.85%) 811 (42.88%) <0.001 498 (41.81%) 313 (44.71%) 0.237
Renal 2,211 (29.49%) 608 (32.15%) 0.026 374 (31.40%) 234 (33.42%) 0.389
Hematologic 937 (12.50%) 326 (17.23%) <0.001 208 (17.46%) 118 (16.85%) 0.783
Metabolic 693 (9.24%) 221 (11.68%) 0.001 139 (11.67%) 82 (11.71%) 1
Neurologic 793 (10.57%) 216 (11.42%) 0.309 119 (9.99%) 97 (13.85%) 0.013
Hepatic 731 (9.75%) 214 (11.31%) 0.047 117 (9.82%) 97 (13.85%) 0.009
Site of infection
Respiratory 1,775 (23.67%) 900 (47.59%) <0.001 620 (52.05%) 280 (40.00%) <0.001
Digestive 950 (12.67%) 219 (11.58%) 0.281 102 (8.56%) 117 (16.71%) <0.001
Genitourinary 275 (3.66%) 80 (4.23%) 1 61 (5.12%) 19 (2.71%) 0.016
Central nervous system 75 (1.01%) 79 (4.17%) <0.001 50 (4.19%) 29 (4.14%) 1
Skin, soft tissue, or bone 153 (2.04%) 32 (1.69%) 0.377 19 (1.59%) 13 (1.85%) 0.809
Circulatory 77 (1.02%) 17 (0.89%) 0.710 13 (1.09%) 4 (0.57%) 0.365
Opportunistic infections 1,428 (19.05%) 931 (49.23%) <0.001 645 (54.16%) 286 (40.86%) <0.001
Candidiasis (pulmonary or esophageal) 78 (1.02%) 82 (4.34%) <0.001 59 (4.95%) 23 (3.29%) 0.109
Cryptococcosis (extrapulmonary) 1 (0.01%) 27 (1.43%) <0.001 18 (1.51%) 9 (1.29%) 0.843
Cytomegalovirus (other than liver, spleen, or nodes) 40 (0.53%) 80 (4.23%) <0.001 70 (5.88%) 10 (1.43%) <0.001
Mycobacterium tuberculosis 76 (1.01%) 82 (4.34%) <0.001 60 (5.04%) 22 (3.14%) 0.066
Pneumocystis jirovecii pneumonia 12 (0.16%) 225 (11.90%) <0.001 195 (16.37%) 30 (4.29%) <0.001
Pneumonia (bacterial), recurrent 1,336 (17.82%) 579 (30.62%) <0.001 367 (30.81%) 212 (30.29%) 0.850
Toxoplasmosis of brain 3 (0.04%) 40 (2.12%) <0.001 33 (2.77%) 7 (1.00%) 0.016
Values are expressed as absolute number (percentage). P values were calculated by χ2 test, and P values in bold indicates statistically significant differences
between groups. HCV, hepatitis C virus; HIV, human immunodeficiency virus.
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cART era was widely perceived as futile, as ICU mortal-
ity was about 70% [38]. Subsequently, cART did not
seem to improve survival in the ICU compared with the
pre-cART era [14,39]. In our study, HIV-infected patients
had higher ICU mortality than the control group. These
differences were regardless of the presence of severe sep-
sis, although it is noted that the ICU mortality was much
more frequent in patients with severe sepsis than in
patients without severe sepsis (other causes). These data
are consistent with several recent reports [12,40,41].
Akgun et al. [40] found higher frequency of medical ICU
admission, 30-day mortality, and mechanical ventilation in
HIV-infected compared with HIV-uninfected patients
[40]. Furthermore, Silva et al. [41] described a more severe
course of sepsis as well as a higher ICU mortality in HIV-
infected patients, and Amancio et al. [12]. reported that
septic shock was associated with higher ICU mortality.
Therefore, according to our data and previously publishedreports, it is not clear whether cART is associated with an
improved survival. In our study, we had no information
about compliance with cART, and we could not distin-
guish between patients with lack of cART initiation and
patients with lack of cART benefit.
In our study, when severe sepsis and mortality in the
HIV-group were compared with the HIV/HCV group,
the data were slightly confusing. The frequency of severe
sepsis in the HIV-group and the HIV/HCV group were
both higher than 50%, and around 5% higher for the
HIV group. Conversely, the ICU mortality was higher in
the HIV/HCV group than in the HIV group at days 7
and 30, but no differences were found at day 90. We
have tried to clarify these complex results through a
competing-risk model, in which we operated with two
different outcome variables (severe sepsis and death) that
compete among themselves to prevent biased results (see
Statistical Analysis section). This analysis shows that HIV/
HCV coinfection (HIV/HCV group) had an increased risk
Table 3 Summary of the cumulative mortality rate at days 7, 30, and 90 in patients admitted to the ICU from 2005 to
2010 according to the presence of severe sepsis
3a: Non-HIV versus all-HIV patients 3b: HIV versus HIV/HCV patients
Control group All HIV group P value(a) HIV group HIV/HCV group P value (b)
(No. = 7,496) (No. = 1,891) (No. = 1.191) (No. = 700)
Day 7 Number of deaths(*) 2,162 690 363 327
Cumulative mortality rate(**)
All patients 28.8 (27.6; 30.1) 36.5 (33.8; 39.2) <0.001 30.5 (27.3; 33.6) 46.7 (41.6; 51.8) <0.001
Patients with severe sepsis 26.1 (24.3; 27.9) 35.3 (31.7; 38.7) <0.001 29.2 (25.4; 33.2) 46.5 (39.6; 53.3) <0.001
Patients without severe sepsis 30.6 (28.9; 32.2) 38.2 (33.9; 42.5) <0.001 32.3 (27.2; 37.4) 47.1 (39.5; 54.5) <0.001
P value(c) <0.001 0.210 0.292 0.941
Day 30 Number of deaths(*) 3819 1285 765 520
Cumulative mortality rate(**)
All patients 50.9 (49.3; 52.5) 67.9 (64.2; 71.7) <0.001 64.2 (59.7; 68.8) 74.3 (67.9; 80.7) <0.001
Patients with severe sepsis 64.0 (61.1; 66.9) 73.8 (68.7; 78.9) <0.001 69.5 (63.3; 75.6) 81.9 (72.8; 90.9) <0.001
Patients without severe sepsis 42.4 (40.5; 44.3) 59.9 (54.6; 65.3) <0.001 56.4 (49.7; 63.2) 65.2 (56.3; 74.1) 0.016
P value(c) <0.001 <0.001 <0.001 <0.001
Day 90 Number of deaths(*) 4419 1531 958 573
Cumulative mortality rate(**)
All patients 58.9 (57.2; 60.7) 80.9 (76.9; 85.1) <0.001 80.4 (75.3; 85.5) 81.9 (75.1; 88.6) 0.484
Patients with severe sepsis 80.6 (77.3; 83.8) 90.7 (85.1; 96.4) <0.001 90.7 (83.7; 97.7) 90.8 (81.2; 99.9) 0.999
Patients without severe sepsis 44.9 (42.9; 46.8) 67.6 (61.8; 73.3) <0.001 65.2 (57.9; 72.4) 71.2 (61.9; 80.4) 0.092
P value(c) <0.001 <0.001 <0.001 <0.001
Values were expressed as follow: (*)absolute count; (**)percentage and 95% confidence interval (95% CI).
P-values were calculated by χ2 test: (a)differences between control group and all HIV group; (b)differences between HIV-group and HIV/HCV group; (c)differences
between severe sepsis and other causes. P-values in bold indicates statistically significant differences between groups. HCV, hepatitis C virus; HIV, human
immunodeficiency virus.
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group), regardless of the presence of severe sepsis. Thus,
the HIV/HCV status per se seems to be deleterious,
independent of severe sepsis.
Liver disease has become a major cause of morbidity
and mortality among HIV/HCV-coinfected patients on
cART, because HIV infection tends to modify the natural
history of CHC toward a faster progression of liver fibrosis
than for HCV-monoinfected patients [22,42,43]. In our
study, about 50% of HIV/HCV-coinfected patients had
comorbidities related to CHC and end-stage liver disease
(ESLD), possibly because of the progressive deterioration
from the underlying chronic liver disorder. Hepatic
cirrhosis has been reported to be a major independent
predictor of ICU mortality, and liver dysfunction results in
a greater mortality burden than HIV status [15]. Further-
more, evidence suggests that during cirrhosis, sepsis is ac-
companied by a markedly imbalanced cytokine response,
which converts responses that are normally beneficial for
fighting infections into excessive, damaging inflammation
[44]. Also, patients with ESLD have enhanced intestinal
permeability (leading to translocation of bacteria and
their products), imbalanced immune reaction, andaggravated intrahepatic microcirculatory dysfunction
and hyperdynamic state, which cause toxin accumula-
tion and immune dysfunction that might further enhance
and perpetuate end-stage organ dysfunction [45]. Never-
theless, the occurrence of life-threatening conditions in
cirrhosis patients is frequent and would explain higher
mortality rates in the HIV/HCV group. [46]. Then, CHC
and cirrhosis should be considered targets for improving
the survival of HIV-infected patients in the ICU in the
future.
The prognostic factors of mortality in HIV-infected
patients admitted to the ICU are acute illness severity,
poor functional status, low albumin rate, and respiratory
failure requiring mechanical ventilation [47-53]. How-
ever, specific HIV characteristics (CD4 cell count, plasma
HIV-RNA load, HIV-related diagnosis, or antiretroviral
therapy) have not been clearly identified as predictors of
ICU mortality [4,15,37,38,49-52,54-59], although some
reports have associated CD4+ cell count with mortality
risk [11,37]. Our study was retrospective, and the acquisi-
tion of the clinical data related to HIV infection and UCI
was unavailable from MBDS records. In addition, other
variables are difficult to control, such as the HCV
Figure 1 Estimated survival for HIV-infected patients who were admitted to the intensive care unit (ICU) from 2005 to 2010 in Spain,
stratified by the presence of severe sepsis (A) or absence of severe sepsis (B). Survival functions were calculated with a competing-risk
model that was developed with a semiparametric bayesian model. HCV, hepatitis C virus; HIV, human immunodeficiency virus.
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use, and the differences between HIV monoinfection and
HIV/HCV coinfection could partially reflect drug use.
In our study, the time to death or discharge was calcu-
lated from hospital rather than ICU admission because
the date of ICU admission was not recorded in the MBDS.
An immortal time bias could have occurred [60,61],
because some patients may have been admitted directly to
ICU, whereas other patients may have survived between
hospital and ICU admission, and this time period was
included in the observation time. However, this theoretic
bias should be well balanced in all groups, and only affect
the basic value of survival time.
Another limitation due to the use of administrative
databases is the inaccuracy in differentiating etiologies of
diseases and the reporting of organ dysfunction, engender-
ing confusion bias. In this context, grouping of ICD-9-CM
codes into comorbidities, organ dysfunction, and site of
infection (Additional file 1: Appendices 1 through 6) may
have represented the best approach to solve this issue.However, the MBDS also provides certain advantages by
being a national clinical administrative database, which
represents large populations from developed countries.
This database has already proven its usefulness in previous
assessments of outcomes among patients admitted to the
ICU [62,63]. Additionally, it allows the detection of trends
in important public health issues.
Conclusions
In conclusion, HIV infection was related to higher fre-
quency of severe sepsis and death among patients admit-
ted to the ICU. Also, HIV/HCV coinfection contributed
to an increased risk of death in both the presence and
absence of severe sepsis.
Key messages
(1) HIV-infected patients had higher frequencies of
severe sepsis and opportunistic infections than did
HIV-seronegative patients.
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http://ccforum.com/content/18/5/475(2) HIV-infected patients had higher mortality than
the control group, independent of the presence of
severe sepsis.
(3) HIV/HCV coinfection (about one third of
HIV-infected patients) had increased risk of
ICU mortality, regardless of the presence of
severe sepsis.
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